Mirum Pharmaceuticals

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Ticker

$MIRM

Sector

Health

Primary listing

NASDAQ

Employees

418

Headquarters

Foster City, United States

Website

www.mirumpharma.com

MIRM Metrics

BasicAdvanced

$7.1bn

-

-$15.17

0.51

-

What the Analysts think about MIRM

Analyst ratings (Buy, Hold, Sell) for Mirum Pharmaceuticals stock.

Bulls say / Bears say

The company raised its 2026 net product sales guidance to $660–$680 million after achieving Q1 net product sales of $159.9 million, underpinned by 55% year-over-year growth in Livmarli sales. (SEC Form 8-K Press Release)

Volixibat’s VISTAS Phase 2b study in primary sclerosing cholangitis met its primary endpoint, with a U.S. NDA submission expected in H2 2026, underscoring pipeline momentum. (SEC Form 8-K Press Release)

Mirum in-licensed zilurgisertib for fibrodysplasia ossificans progressiva, with the FDA’s acceptance of the NDA and a Priority Review PDUFA date of September 26, 2026, potentially adding a new rare disease product this year. (SEC Form 8-K Press Release)

Net loss for Q1 2026 was $790.2 million—driven largely by a $726.3 million in-process R&D expense—bringing the accumulated deficit to $1.5 billion and weighing on profitability. (SEC Q1 2026 Form 10-Q)

As of March 31, 2026, Mirum held only $420.6 million in cash, cash equivalents, and investments against ongoing high operating expenses and expected continued net losses, raising cash runway concerns. (SEC Q1 2026 Form 10-Q)

Mirum faces increasing competition in its core Livmarli franchise from Ipsen’s odevixibat (Bylvay/Kayfanda) in ALGS and PFIC, and Alfasigma’s linerixibat poised for approval in 2026, potentially eroding market share. (SEC Q1 2026 Form 10-Q)

Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2026.

MIRM Financial Performance

Revenues and expenses

Income statement
QuarterlyAnnual	Q3 24	QoQ growth
Revenue	$37bn	-39.75%
Net income	$45bn	107.52%
Profit margin	37.65%	6.78%

MIRM Earnings Performance

Company profitability

Earnings per share
QuarterlyAnnual	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24
Actual	$3.69	$2.85	$2.45	$2.42	-
Expected	$3.55	$2.61	$2.05	$2.31	$3.94
Surprise	3.94%	9.20%	19.51%	4.63%	-

MIRM News

AllArticlesVideos

Biotech ETF Index Surges 10% After Rebalance

ETF Trends·4 weeks ago